Novotech Honored with Frost & Sullivan’s 2024 Best Practices Company of the Year Award for Leadership in Biotech CRO Services
10.9.2024 22:20:00 EEST | Business Wire | Press release
Novotech, the global full-service clinical Contract Research Organization (CRO), is proud to announce that it has been awarded the prestigious 2024 Global Company of the Year Award by Frost & Sullivan. This recognition underscores Novotech’s commitment to accelerating clinical development for biotech companies through innovative solutions, advanced analytics, and a comprehensive global reach.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240910876910/en/
(Graphic: Business Wire)
Frost & Sullivan’s award honors Novotech’s innovative full-service approach that accelerates clinical development through advanced analytics, access to diverse patient populations, and through specialized technology.
“Overall, Novotech distinguishes itself in the ever-expanding CRO market by successfully addressing the complex regulatory landscape with a deep understanding of local regulations and overcoming cultural barriers to establish itself as a truly global CRO. As a result, the company progresses closer to becoming a preferred global partner with regional leadership and localized expertise,” said Unmesh Lal, Global Research Director at Frost & Sullivan.
Unmatched Global Reach and Expertise
Novotech's extensive global footprint allows the company to provide tailored solutions that address the unique regulatory and cultural nuances of each market. This strategic advantage facilitates faster patient recruitment and enhanced trial efficiency, ensuring successful outcomes for its biotech clients. Novotech's project manager-centric model ensures seamless communication and effective execution of clinical trials, fostering strong, collaborative relationships with clients.
Commitment to Innovation and Advanced Technology
A key element in being awarded this accolade is Novotech continuing to leverage cutting-edge technology to enhance clinical trial operations. The company's ongoing investments in artificial intelligence (AI), big data analytics, digital clinical trials, and cloud-based software platforms significantly improve data quality, trial planning, and transparency in communications with stakeholders. Partnerships with industry leaders like Veeva and Medidata further empower Novotech’s clients to optimize their drug development programs.
Recognition of Excellence
Frost & Sullivan first recognized Novotech with their award for best APAC CRO in 2006, and Novotech has continued to win this award every year since. Receiving, for the first time, Frost & Sullivan’s 2024 Global Company of the Year Award is tangible evidence of Novotech’s drive for constant improvement and creating optimal outcomes for our partners and clients.
“We are honored to receive the 2024 Global Company of the Year Award from Frost & Sullivan,” said Dr. John Moller, CEO of Novotech. “This recognition is a testament to the hard work and dedication of our team, our commitment to innovation, and our unwavering focus on delivering exceptional results for our biotech and pharmaceutical clients. We are proud to be at the forefront of advancing clinical development and to be acknowledged as a leader in the CRO industry.”
Frost & Sullivan Best Practices Awards recognize companies in various regional and global markets for demonstrating outstanding achievement and superior performance in leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analyses, and extensive secondary research to identify best practices in the industry.
About NovotechNovotech-CRO.com
Founded in 1997, Novotech is a global full-service clinical Contract Research Organization (CRO) focused on partnering with biotech companies to accelerate the development of advanced and novel therapeutics at every phase.
Recognized for its industry-leading contributions, Novotech has received numerous prestigious awards, including the CRO Leadership Award 2023, the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence 2023, the Asia-Pacific Contract Research Organization Company of the Year Award since 2006.
The Company offers a comprehensive suite of services including laboratories, Phase I facilities, drug development consulting, regulatory expertise, and has experience with over 5,000 clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. With a presence in 34 office locations and a dedicated team of 3,000+ professionals worldwide, Novotech is a trusted end-to-end strategic partner of choice.
For more information or to speak to an expert team member visit www.Novotech-CRO.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20240910876910/en/
Contacts
Media
Toyna Chin
mediacontact@novotech-cro.com
USA: +1 415 364 8135
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fortegra Completes Acquisition by DB Insurance29.5.2026 23:30:00 EEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 23:01:00 EEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom